{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:05:32Z","timestamp":1778335532035,"version":"3.51.4"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["EY14231"],"award-info":[{"award-number":["EY14231"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Explore the association of patient baseline age with response to anti-vascular endothelial growth factor treatment for diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>One thousand six eyes assigned to anti-vascular endothelial growth factor treatment in 3 DRCR Retina Network randomized trials for diabetic macular edema were included. Age was classified into four levels: younger than 50, 50 to 59, 60 to 69, and 70 years or older. The associations between age with change in visual acuity and central subfield thickness from baseline and with weak treatment response in visual acuity and central subfield thickness not meeting prespecified thresholds over 2 years were assessed, controlling for trial, anti-vascular endothelial growth factor agent, and potential confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At 2 years, the average improvement from baseline decreased with older age for visual acuity (youngest to oldest: +17.9 to +9.0 letters;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and central subfield thickness (\u2212183\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m to \u2212158\n                      <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>\n                      m;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.02). The cumulative proportion of weak response in visual acuity (60%\u201384%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.001) and central subfield thickness (42%\u201362%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009) increased with older age. These trends were present in all anti-vascular endothelial growth factor subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Less improvement from baseline and greater likelihood of weak treatment response in visual acuity and central subfield thickness were observed among older patients. These findings may help refine expectations of treatment outcomes when initiating anti-vascular endothelial growth factor therapy for diabetic macular edema.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/iae.0000000000004707","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:03:00Z","timestamp":1761224580000},"page":"438-448","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["ASSOCIATION OF PATIENT AGE WITH RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR TREATMENT OF DIABETIC MACULAR EDEMA"],"prefix":"10.1097","volume":"46","author":[{"given":"Danni","family":"Liu","sequence":"first","affiliation":[{"name":"Jaeb Center for Health Research, DRCR Retina Network, Tampa, Florida;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen G.","family":"Maguire","sequence":"additional","affiliation":[{"name":"Jaeb Center for Health Research, DRCR Retina Network, Tampa, Florida;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowtham","family":"Jonna","sequence":"additional","affiliation":[{"name":"Austin Research Center for Retina, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee M.","family":"Jampol","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leanne T.","family":"Labriola","sequence":"additional","affiliation":[{"name":"Pittsburgh Clinical Trial Consortium, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F.","family":"Martin","sequence":"additional","affiliation":[{"name":"Emory Eye Center, Atlanta, Georgia; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K.","family":"Sun","sequence":"additional","affiliation":[{"name":"Joslin Diabetes Center, Beetham Eye Institute, Harvard Department of Ophthalmology, Boston, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the DRCR Retina Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260217","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","article-title":"Prevalence of and risk factors for diabetic macular edema in the United States","volume":"132","author":"Varma","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"R3-20260217","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.ophtha.2010.02.031","article-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"117","author":"Elman","year":"2010","journal-title":"Ophthalmology"},{"key":"R4-20260217","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"key":"R5-20260217","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"R6-20260217","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1136\/bjophthalmol-2016-308388","article-title":"Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature","volume":"100","author":"Ashraf","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R7-20260217","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.ophtha.2015.02.036","article-title":"Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"122","author":"Sophie","year":"2015","journal-title":"Ophthalmology"},{"key":"R8-20260217","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archophthalmol.2012.1107","article-title":"Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab","volume":"130","author":"Bressler","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R9-20260217","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/eye.2013.245","article-title":"Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab","volume":"28","author":"Channa","year":"2014","journal-title":"Eye (Lond)"},{"key":"R10-20260217","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa2204225","article-title":"Aflibercept monotherapy or bevacizumab first for diabetic macular edema","volume":"387","author":"Jhaveri","year":"2022","journal-title":"N Engl J Med"},{"key":"R11-20260217","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.ophtha.2024.01.037","article-title":"Risk factors for meeting criteria for switching from bevacizumab to aflibercept when treating eyes with diabetic macular edema and visual acuity of <20\/40","volume":"131","author":"Jhaveri","year":"2024","journal-title":"Ophthalmology"},{"key":"R12-20260217","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-20260217","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1167\/iovs.12-10290","article-title":"Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg spectralis optical coherence tomography","volume":"53","author":"Chalam","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-20260217","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"R15-20260217","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/IAE.0000000000003730","article-title":"Defining \u201cstrong\u201d versus \u201cweak\u201d response to anti-vascular endothelial growth factor treatment for center-involved diabetic macular edema","volume":"43","author":"Sun","year":"2023","journal-title":"Retina"},{"key":"R16-20260217","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1214\/aos\/1176350366","article-title":"High breakdown-point and high efficiency robust estimates for regression","volume":"15","author":"Yohai","year":"1987","journal-title":"Ann Stat"},{"key":"R17-20260217","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40942-022-00434-9","article-title":"Effect of age on response to anti-VEGF agents in patients with center involving diabetic macular edema in a tertiary hospital","volume":"8","author":"Alshalan","year":"2022","journal-title":"Int J Retina Vitreous"},{"key":"R18-20260217","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"key":"R19-20260217","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamaophthalmol.2018.6786","article-title":"Factors associated with visual acuity and central subfield thickness changes when treating diabetic macular edema with anti-vascular endothelial growth factor therapy: an exploratory analysis of the protocol T randomized clinical trial","volume":"137","author":"Bressler","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"R20-20260217","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bjophthalmol-2013-303168","article-title":"Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5)","volume":"97","author":"Sivaprasad","year":"2013","journal-title":"Br J Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004707","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:00:17Z","timestamp":1771347617000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000004707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000004707","relation":{},"ISSN":["0275-004X","1539-2864"],"issn-type":[{"value":"0275-004X","type":"print"},{"value":"1539-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}